PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: PhosphonicS Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability - An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries - Phosphonics.com
PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability

 

NewswireToday - /newswire/ - Abingdon, Oxford, United Kingdom, 2015/11/12 - An exciting new acid catalyst from PhosphonicS could help significantly reduce costs and minimise losses in the Pharmaceutical and Chemical industries - Phosphonics.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The recently launched Phos-Cat4 has been specially designed to be just as effective as the rest of the PhosphonicS acid catalyst range but offer even more stability.

The PhosphonicS range of catalysts, which are designed specifically to simplify and streamline processes, use patented technology for attaching a variety of functionalities to a silica backbone. This range of products can be considered as alternatives to traditional homogeneous acids, with all the same chemical characteristics, whilst also benefitting from all the advantages of an immobilised reagent. These clean, efficient catalysts can be used from lab to plant scale across a range of transformations including esterification, elimination, protection and deprotection, rearrangement, cyclisation and hydrolysis reactions.

Phos-Cat4’s key benefits include:

• Reduced operating costs no additional washes are required;
• Lower waste disposal costs reduced discharge minimises environmental impact;
• No additional purification required prevents formation of genotoxic by-product impurities associated with sulfuric acids;
• Reduced overall production costs catalysts can easily be recycled for reuse;
• Increased stability.

Features of the PhosphonicS acid catalyst product range include:

• Easy to handle, free flowing solid;
• High acid strengths comparable to traditional acids;
• High chemical and physical stability;
• No pre-treatment required, no swelling;
• Can be applied in either fixed-bed (continuous) or slurry (batch) mode.

Alongside the range of products PhosphonicS (phosphonics.com) provide, they also have a team of scientists available to support customers throughout the evaluation of their products. In-house screening and testing programs are available along with full engineering support services and customised research and development programmes.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: PhosphonicS Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


PhosphonicS Introduces New Acid Catalyst Offering Significant Cost Reductions with Increased Stability

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Rob Gibbs - Phosphonics.com 
+44(0)12 3583 4466 rob.gibbs[.]phosphonics.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any PhosphonicS Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From PhosphonicS Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)